An open-label study to evaluate the effectiveness and safety of Ocrelizumab in patients with relapsing remitting multiple sclerosis who have had a suboptimal response to an adequate course of disease-modifying treatment
Dr. Emmanuelle Waubant
is currently recruiting for a clinical research study to evaluate the effect of ocrelizumab in patients with relapsing remitting multiple sclerosis who had suboptimal response to other disease modifying treatment for MS. Patients who have a diagnosis of relapsing remitting MS, and aged 18 to 55 may qualify for the study. Study participants must be treated with no more than 2 prior disease modifying therapies, each of the treatment duration should have been at least for 6 months, and the treatment discontinued for lack of efficacy. The study involves study visits to the study center, and total duration of the study is about 2-3 years. The study procedures include physical exam, completing questionnaires, testing of blood samples, and magnetic resonance imaging (MRI). Study medication will be given intravenously, and the total treatment period is for 96 weeks. The cost of study procedures including the MRI are covered by the study.